ESMO Gastrointestinal Oncology最新文献

{"title":"Lymph node mapping-based optimal bowel-resection margin and central radicality in colon cancer surgery: an international, prospective, observational cohort study","authors":"H. Ueno ,&nbsp;N.K. Kim ,&nbsp;J.C. Kim ,&nbsp;P. Tsarkov ,&nbsp;W. Hohenberger ,&nbsp;R. Grützmann ,&nbsp;N.E Samalavičius ,&nbsp;A. Dulskas ,&nbsp;J.-T. Liang ,&nbsp;P. Quirke ,&nbsp;N. West ,&nbsp;A. Shiomi ,&nbsp;M. Ito ,&nbsp;M. Shiozawa ,&nbsp;K. Komori ,&nbsp;K. Matsuda ,&nbsp;Y. Kinugasa ,&nbsp;T. Sato ,&nbsp;K. Yamada ,&nbsp;Y. Hashiguchi ,&nbsp;K. Sugihara","doi":"10.1016/j.esmogo.2025.100231","DOIUrl":"10.1016/j.esmogo.2025.100231","url":null,"abstract":"<div><h3>Background</h3><div>Substantial variations in the extent of lymphadenectomy are acknowledged internationally in colon cancer surgery because essential data for standardization, including the anatomical distribution of metastatic lymph nodes (LN), are lacking.</div></div><div><h3>Materials and methods</h3><div>Pre-specified LN mappings based on <em>in vivo</em> bowel measurements were conducted for stages I-III colon cancer patients treated at 31 leading hospitals in six countries. The extent of lymphadenectomy was classified from levels A (pericolic) to C (central LNs) according to the pre-specified anatomical landmarks. The primary outcome was the extent of pericolic lymphatic spread and the incidence of metastasis in central LNs, and secondary ones included the real-world status of central radicality and its association with short-term outcomes.</div></div><div><h3>Results</h3><div>Among 3647 patients, pericolic spread beyond 10 cm (0.2%) and absence of feeding arteries supplying the bowel within 10 cm from the primary tumor (0.3%) were rare, irrespective of nationality. The incidence of metastasis in central LNs was ∼3% (range: 0.2% in T1 to 7% in T4 tumors) and was lower in tumors located at the splenic flexure (0.5%). The proportion of patients with level C radicality was ∼76%, which was statistically significantly associated with T stage only in one country. A higher radicality level conferred no adverse impact on either the incidence of Clavien–Dindo grade ≥III or 30-day mortality.</div></div><div><h3>Conclusions</h3><div>The ‘10-cm rule’ could be an international criterion for determining the bowel-resection margin. Central lymphadenectomy is feasible internationally, though the indication should be selective, not routine, depending on the stage and location of the primary tumor.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study","authors":"A. Sartore-Bianchi ,&nbsp;F. Toscano ,&nbsp;D.P. Bernasconi ,&nbsp;A. Curaba ,&nbsp;P. Colombo ,&nbsp;C. Mazzali ,&nbsp;A. Piantelli ,&nbsp;A. Dotti ,&nbsp;D. Tedesco ,&nbsp;K. Bencardino ,&nbsp;A. Amatu ,&nbsp;F. Tosi ,&nbsp;E. Bonazzina ,&nbsp;F. Villa ,&nbsp;V. Gori ,&nbsp;D. Piscazzi ,&nbsp;A.G. Agostara ,&nbsp;G. Calvanese ,&nbsp;G. Saporetti ,&nbsp;S. Siena","doi":"10.1016/j.esmogo.2025.100224","DOIUrl":"10.1016/j.esmogo.2025.100224","url":null,"abstract":"<div><h3>Background</h3><div>Patient-reported experience measures (PREMs) offer an objective measure of the patient experience by investigating various fields of the care pathway. We analyzed PREMs in patients with metastatic colorectal cancer (mCRC) undergoing anticancer therapy integrating an auditing process to allow corrective actions.</div></div><div><h3>Materials and methods</h3><div>This is a prospective, observational, monocentric study with a four-phase sequential design: phase I validation of the PREMs questionnaires in five-level Likert item format in Italian; phase II administration of questionnaires at T0 (0-30 days since the start of oncology care), T1 (30 days-6 months), T2 (6-12 months), T3 (&gt;12 months); phase III analysis of results during quality audits and implementation of strategies to improve care pathways; phase IV re-administration and results compared with phase II.</div></div><div><h3>Results</h3><div>PREMs were tested for validity in 47 patients (phase I of the EPIC study). In phase II, 102 patients were enrolled, 150 questionnaires were administered and 142 returned (94.6%). Sixteen questions grouped in four areas (information about care path, contacts and accessibility, patient needs, health care awareness monitoring) were analyzed. A high proportion of patients were concerned about their future/possibility of relapse at T1 (61.6%/58.3%) and T2 (62.5%/63.7%). After the implementation of a checklist for clinicians (phase III), in phase IV, 74 patients were enrolled and the proportion of patients concerned about their future/possibility of a relapse decreased at T1 (35.7%/25%) and T2 (31.3%/43.4%).</div></div><div><h3>Conclusions</h3><div>PREMs evaluation is feasible in the setting of mCRC. A checklist for clinicians tailored after an <em>ad hoc</em> audit improved results about patients’ concerns about their future and possibility of relapse.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of tumor-associated microbiome in multifocal small intestinal neuroendocrine tumors (SI-NETs)","authors":"I.T. Lee ,&nbsp;A. Dohlman ,&nbsp;T. Gao ,&nbsp;Z. Zhang ,&nbsp;Y. Kasai ,&nbsp;G.E. Kim ,&nbsp;C. Thirlwell ,&nbsp;E. Nakakura ,&nbsp;M. Meyerson ,&nbsp;N. Mäkinen","doi":"10.1016/j.esmogo.2025.100229","DOIUrl":"10.1016/j.esmogo.2025.100229","url":null,"abstract":"<div><h3>Background</h3><div>Small intestinal neuroendocrine tumors (SI-NETs) are among the most common neoplasms of the small bowel; however, the molecular mechanisms underlying their pathogenesis are largely unknown. The multifocal nature of SI-NETs, their putative distinct genomic origins, and their enrichment in the distal ileum led us to hypothesize that environmental factors, such as pathogenic organisms, might play a role in the development of these lesions.</div></div><div><h3>Materials and methods</h3><div>To study the tumor-associated microbiome of multifocal SI-NETs and its potential role in pathogenesis, we used matched whole genome and transcriptome sequencing data from a cohort of 10 multifocal SI-NET patients, including 70 primary ileal NETs and their matched normal ileal mucosa and/or whole blood specimens.</div></div><div><h3>Results</h3><div>Microbial communities in the ileal tissue samples were primarily composed of bacteria. The most abundant genera included well-known gastrointestinal, oral, and mucosal bacteria. Ileal tissue samples from individual patients contained distinct patient-specific microbial communities. Although the microbiota composition did not show significant differences between ileal NET and normal ileal tissues, genus <em>Propionibacterium</em> was found to be enriched in the normal tissue specimens.</div></div><div><h3>Conclusions</h3><div>This study comprehensively characterizes the tissue-resident ileal microbiome of multifocal SI-NET patients. We provide clear evidence that the microbial communities in the ileum are largely patient specific, whereas our genus-level analyses suggest that SI-NET pathogenesis is unlikely driven by individual microorganisms present in the tumors at the time of surgical resection.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100229"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients","authors":"F. Salvà ,&nbsp;G. Catani ,&nbsp;N. Saoudi ,&nbsp;I. Baraibar ,&nbsp;J. Ros ,&nbsp;M. Rodriguez ,&nbsp;C. Salvà de Torres ,&nbsp;A. Alcaraz ,&nbsp;A. Garcia ,&nbsp;R. Comas ,&nbsp;F. Ruiz-Pace ,&nbsp;A. Rezqallah ,&nbsp;R. Dienstmann ,&nbsp;J. Tabernero ,&nbsp;E. Elez","doi":"10.1016/j.esmogo.2025.100230","DOIUrl":"10.1016/j.esmogo.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>Oxaliplatin, a key agent used for managing metastatic colorectal cancer (mCRC), is often discontinued due to cumulative toxicity. Its reintroduction in later treatment lines remains a common clinical practice, despite the absence of robust prospective trials supporting this therapeutic strategy. This study aimed to evaluate the efficacy of oxaliplatin rechallenge in refractory mCRC and to identify patient characteristics predictive of improved outcomes with this approach.</div></div><div><h3>Patients and methods</h3><div>We retrospectively analyzed patients treated with oxaliplatin in the third- or fourth-line setting at Vall d’Hebron Hospital between 2015 and 2021. Outcomes included overall response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS). Patients achieving median PFS &gt;6 months were classified as best-responders. Factors affecting PFS were analyzed with a Cox regression model. Amplicon-seq analysis of 61 genes was carried out using Illumina technology.</div></div><div><h3>Results</h3><div>Of 735 patients receiving third- or fourth-line treatment, 102 (14%) received oxaliplatin retreatment (69% in third line; 31% in fourth line). Median PFS was 4.0 months (95% CI 3.29-5.03 months), with an ORR of 12% and DCR of 39%. Twenty-eight patients (27%) were best-responders. Predictors of efficacy included response to first-line oxaliplatin, planned oxaliplatin discontinuation, and an oxaliplatin-free interval of at least 22.0 months. No significant associations were identified between molecular alterations and prognostic subgroups.</div></div><div><h3>Conclusions</h3><div>Oxaliplatin-based reintroduction therapy is a viable strategy in mCRC, particularly for patients with a favorable prior response and prolonged oxaliplatin-free intervals. However, identifying more precise biomarkers is essential to improve patient selection and maximize treatment efficacy.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations","authors":"J. Ros ,&nbsp;V. Navarro ,&nbsp;G. Villacampa ,&nbsp;I. Baraibar ,&nbsp;F. Salvà ,&nbsp;M. Rodriguez ,&nbsp;C. Vaghi ,&nbsp;A. Garcia ,&nbsp;A. Alcaraz ,&nbsp;J. Tabernero ,&nbsp;E. Élez ,&nbsp;R. Dienstmann","doi":"10.1016/j.esmogo.2025.100225","DOIUrl":"10.1016/j.esmogo.2025.100225","url":null,"abstract":"<div><h3>Background</h3><div>The <em>BRAF</em> V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with <em>BRAF</em> V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with <em>BRAF</em> V600E-mutant colorectal cancer treated with either BRAF inhibitor combinations or chemotherapy.</div></div><div><h3>Materials and methods</h3><div>A systematic review was carried out to identify clinical trials or real-world cohorts evaluating patients with <em>BRAF</em>-mutant colorectal cancer treated either with chemotherapy or BRAF inhibitor combinations. A control cohort of melanoma patients treated with BRAF inhibitors in a phase III randomized trial was included. Adjusted <em>R</em>² (<em>R</em>²_adj) values were calculated to quantify the association between surrogate endpoints and median OS.</div></div><div><h3>Results</h3><div>Overall, a total of 5227 patients included in 29 cohorts were analyzed. Among patients with colorectal cancer treated with chemotherapy, overall response rate (ORR) and disease control rate (DCR) showed a high correlation with OS (<em>R</em>²_adj &gt; 0.90). Among patients treated with targeted therapy, progression-free survival (PFS) showed the highest correlation with OS (<em>R</em>²_adj = 0.90). In the melanoma cohort, PFS was strongly associated with OS (<em>R</em>²_adj = 0.92).</div></div><div><h3>Conclusions</h3><div>In <em>BRAF</em>-mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy","authors":"K. Sugiyama ,&nbsp;S. Kumar ,&nbsp;A. Chaudry ,&nbsp;N. Patel ,&nbsp;P. Patel ,&nbsp;D. Cunningham ,&nbsp;N. Starling ,&nbsp;S. Rao ,&nbsp;C. Fribbens ,&nbsp;L. Eldridge ,&nbsp;I. Chau","doi":"10.1016/j.esmogo.2025.100223","DOIUrl":"10.1016/j.esmogo.2025.100223","url":null,"abstract":"<div><h3>Background</h3><div>Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment.</div></div><div><h3>Materials and methods</h3><div>We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria.</div></div><div><h3>Results</h3><div>A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, <em>P</em> &lt; 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, <em>P</em> &lt; 0.001). A decreased PNI (<em>P</em> = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, <em>P</em> = 0.75).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100223"},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany","authors":"S. Lonardi ,&nbsp;K. Potthoff ,&nbsp;L. Procaccio ,&nbsp;C. Yoo ,&nbsp;T. Macarulla ,&nbsp;F. Hedouin-Biville ,&nbsp;G.W. Prager","doi":"10.1016/j.esmogo.2025.100217","DOIUrl":"10.1016/j.esmogo.2025.100217","url":null,"abstract":"<div><div>Pancreatic cancer (PAC) is an aggressive disease with poor clinical outcomes. Liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) is the only approved therapy for metastatic PAC following gemcitabine-based therapy, based on the survival benefit demonstrated in the phase III NAPOLI-1 trial. Factors associated with long-term survival in this trial included age ≤65 years, Karnofsky performance status (KPS) ≥90, neutrophil-to-lymphocyte (N/L) ratio ≤5, carbohydrate antigen (CA) 19-9 &lt;59-times the upper limit of normal (ULN), and no liver metastases. Using real-world data from studies conducted in Korea, Italy, and Germany, this review aims to assess the suitability of prognostic factors identified in the NAPOLI-1 trial nomogram. In these real-world studies, a high CA19-9 level and a low N/L ratio were associated with long-term survival in patients treated with nal-IRI+5-FU/LV. The impact of albumin levels, body mass index (BMI), liver metastasis, and KPS on survival identified from the NAPOLI-1 trial was confirmed in some real-world analyses but not consistently. Factors such as patient age and number of previous lines of treatment that were not identified in the NAPOLI-1 nomogram may be associated with long-term survival with nal-IRI+5-FU/LV in the real-world. In conclusion, this review has shown that while prognostic factors are useful for patient stratification, their predictive value on the efficacy of nal-IRI+5-FU/LV is low, thus this treatment may also result in long-term survival in patients with apparently unfavorable characteristics.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy","authors":"M. Sugimori ,&nbsp;A. Hirotani ,&nbsp;H. Yamazaki ,&nbsp;M. Oshi ,&nbsp;K. Kawashima ,&nbsp;H. Tsuchiya ,&nbsp;Y. Kanemaru ,&nbsp;Y. Suzuki ,&nbsp;S. Onodera ,&nbsp;H. Miwa ,&nbsp;A. Nozaki ,&nbsp;K. Sugimori ,&nbsp;C. Kunisaki ,&nbsp;M. Kudo ,&nbsp;M. Morimoto ,&nbsp;S. Maeda","doi":"10.1016/j.esmogo.2025.100221","DOIUrl":"10.1016/j.esmogo.2025.100221","url":null,"abstract":"<div><h3>Background</h3><div>Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) therapies are widely used to treat advanced pancreatic ductal adenocarcinoma (PDAC). This study aimed to identify the prognostic factors associated with these regimens, focusing on key genomic alterations in the ‘Big Four’ genes (<em>KRAS, TP53, CDKN2A,</em> and <em>SMAD4</em>).</div></div><div><h3>Materials and methods</h3><div>This retrospective observational study analysed real-world data from 5205 PDAC patients registered in the national database, Center for Cancer Genomics and Advanced Therapeutics (C-CAT), who underwent comprehensive genomic profiling between June 2019 and December 2023 in Japan. Clinical characteristics and genomic alterations were analysed. Time to progression (TTP) was compared between patients treated with GnP or FFX as first-line therapy. Gene alterations were classified as truncating or missense mutations to assess prognostic relevance.</div></div><div><h3>Results</h3><div>GnP was more frequently selected than FFX as first-line treatment (2315 versus 1181). FFX was more commonly used in younger, male patients without prior adjuvant therapy. After matching for age, sex, and adjuvant history, GnP demonstrated superior TTP compared with FFX (median TTP: 6.0 versus 5.5 months, <em>P</em> = 0.019). In the GnP group, <em>TP53</em> alterations were associated with significantly shorter TTP compared with wild-type <em>TP53</em> (median TTP: 5.8 versus 7.0 months; <em>P</em> &lt; 0.0001). Furthermore, truncating <em>TP53</em> mutations were linked to shorter TTP than missense mutations (median TTP: 5.3 versus 5.9 months; <em>P</em> = 0.021).</div></div><div><h3>Conclusions</h3><div>In Japanese real-world data, GnP showed superior TTP compared with FFX for advanced PDAC. <em>TP53</em> status may serve as a prognostic biomarker in patients receiving GnP therapy.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100221"},"PeriodicalIF":0.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144813910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controversies in upper GI oncology: definition and management of oligometastatic gastroesophageal adenocarcinoma","authors":"A. Petrillo ,&nbsp;G. Piessen ,&nbsp;H.W.M. van Laarhoven","doi":"10.1016/j.esmogo.2025.100228","DOIUrl":"10.1016/j.esmogo.2025.100228","url":null,"abstract":"","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144813911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ESMO Podcast on upper gastrointestinal cancers-highlights in biliary and pancreatic cancers from ASCO 2025.","authors":"J Dekervel, F Castet, A Vogel","doi":"10.1016/j.esmogo.2025.100220","DOIUrl":"https://doi.org/10.1016/j.esmogo.2025.100220","url":null,"abstract":"","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"100220"},"PeriodicalIF":0.0,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146128439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}